225.57MMarket Cap-4.08P/E (TTM)
0.7999High0.7300Low21.58MVolume0.7510Open0.7679Pre Close16.68MTurnover7.51%Turnover RatioLossP/E (Static)291.32MShares2.105052wk High5.57P/B222.48MFloat Cap0.457852wk Low--Dividend TTM287.33MShs Float778.1999Historical High--Div YieldTTM9.10%Amplitude0.1700Historical Low0.7720Avg Price1Lot Size
Ocugen Stock Forum
GlobeNewswire· 5 mins ago
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis
Grabbed a few at .88. It usually hovers around $1-2, a little upside
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
No comment yet